Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy

Journal of Neurosurgery

Volumn 123, Issue 3, 2015, Pages 760-770

  Reulen, Hans Juergen ^a   Poepperl, Gabriele ^b   Goetz, Claudia ^a   Gildehaus, Franz Joseph ^b   Schmidt, Michael ^c   Tatsch, Klaus ^b   Pietsch, Torsten ^d   Kraus, Theo ^a   Rachinger, Walter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b University Vim   (Germany)

^c Institute of Medical Informatics Biometry and Epidemiology   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Anaplastic astrocytoma; Glioblastoma; I 131?labeled anti tenascin mAB; Oncology; Radioimmunoconjugate; Radioimmunotherapy

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; IODINE 131; IODINE 131 TENASCIN MONOCLONAL ANTIBODY; LOMUSTINE; MONOCLONAL ANTIBODY; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; TENASCIN; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90; YTTRIUM 90 TENASCIN MONOCLONAL ANTIBODY;

ADULT; AGED; ANTICONVULSANT THERAPY; APHASIA; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DYSPHASIA; ERYTHROPENIA; FEMALE; FOLLOW UP; FRACTIONATED INTRACAVITARY RADIOIMMUNOTHERAPY; GLIOBLASTOMA; HEADACHE; HEMIPARESIS; HUMAN; HYDROCEPHALUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE DISTRIBUTION; RADIATION NECROSIS; RADIOIMMUNOTHERAPY; SEIZURE; SKIN NECROSIS; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; ASTROCYTOMA; BRAIN NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84952716932     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.12.JNS142168     Document Type: Article

References (39)

1. Aaslid R, Gröger U, Patlak CS, Fenstermacher JD, Huber P, Reulen HJ: Fluid flow rates in human peritumoural oedema. Acta Neurochir Suppl (Wien) 51:152-154, 1990
2. Anglemyer A, Horvath HT, Bero L: Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 4:MR000034, 2014
3. Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, et al: Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46:1042-1051, 2005
4. Akabani G, Reist CJ, Cokgor I, Friedman AH, Friedman HS, Coleman RE, et al: Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med 40:631-638, 1999
5. Balza E, Siri A, Ponassi M, Caocci F, Linnala A, Virtanen I, et al: Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 332:39-43, 1993
6. Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC: Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77:996-1001, 2010
7. Casacó A, López G, García I, Rodríguez JA, Fernández R, Figueredo J, et al: Phase I single-dose study of intracavitaryadministered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 7:333-339, 2008
8. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993
9. De Bonis P, Lofrese G, Anile C, Pompucci A, Vigo V, Mangiola A: Radioimmunotherapy for high-grade glioma. Immunotherapy 5:647-659, 2013
10. Gaspar LE, Fisher BJ, Macdonald DR, LeBer DV, Halperin EC, Schold SC Jr, et al: Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55-57, 1992
11. Gildehaus FJ, Rachinger W, Decker M, Stocker S, Goetz C, Poepperl G, et al: Migration properties of a radiolabeled intact antibody and Fab-fragment after locoregional application in C6 glioma of the rat. J Nucl Med 44 Suppl:36P, 2003 (Abstract)
12. Goetz C, Riva P, Poepperl G, Gildehaus FJ, Hischa A, Tatsch K, et al: Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 62:321-328, 2003
13. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH: Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98:362-369, 2002
14. Hdeib A, Sloan A: Targeted radioimmunotherapy: the role of ?I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas. Future Oncol 8:659-669, 2012
15. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT: A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 34:121-131, 1995
16. Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Münzel M, et al: Low values of 5-hydroxymethylcytosine (5hmC), the sixth base, are associated with anaplasia in human brain tumors. Int J Cancer 131:1577-1590, 2012
17. Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ Jr, et al: Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623-630, 2011
18. Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, et al: A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg 113:192-198, 2010
19. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563-2569, 2006
20. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385, 2005
21. Nakagawa H, Groothuis DR, Owens ES, Fenstermacher JD, Patlak CS, Blasberg RG: Dexamethasone effects on [125I] albumin distribution in experimental RG-2 gliomas and adjacent brain. J Cereb Blood Flow Metab 7:687-701, 1987
22. Pichlmeier U, Bink A, Schackert G, Stummer W: Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 10:1025-1034, 2008
23. Pöpperl G, Götz C, Gildehaus FJ, Yousry TA, Reulen HJ, Hahn K, et al: [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV).] Nuklearmedizin 41:120-128, 2002 (Ger)
24. Pöpperl G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC, et al: Serial O-(2-[(18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 33:792-800, 2006
25. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE II, et al: Phase II trial of murine (131) I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389-1397, 2002
26. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE II, et al: A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 10:182-189, 2008
27. Reardon DA, Zalutsky MR, Bigner DD: Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther 7:675-687, 2007
28. Reulen HJ, Graham R, Spatz M, Klatzo I: Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J Neurosurg 46:24-35, 1977
29. Riva P, Arista A, Tison V, Sturiale C, Franceschi G, Spinelli A, et al: Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer 73 (3 Suppl):1076-1082, 1994
30. Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, et al: Loco-regional radioimmunotherapy of highgrade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res 5 (10 Suppl):3275s-3280s, 1999
31. Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM, et al: 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-phase I and II study. Acta Oncol 38:351-359, 1999
32. Sminia P, Mayer R: External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain. Cancers (Basel) 4:379-399, 2012
33. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392-401, 2006
34. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
35. Thomas AA, Omuro A: Current role of anti-angiogenic strategies for glioblastoma. Curr Treat Options Oncol 15:551-566, 2014
36. Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W, et al: Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res 14:7330-7339, 2008
37. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD: Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36:41-55, 1992
38. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM: Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 31:508-511, 1990
39. Zalutsky MR, Bigner DD: Radioimmunotherapy with alphaparticle emitting radioimmunoconjugates. Acta Oncol 35:373-379, 1996